News | October 22, 2007

Osteoporosis Imaging to Predict Heart Attacks, Stroke

October 23, 2007 - Hologic Inc. today announced that a study has been published online in the Journal of Bone and Mineral Research that used single-energy vertebral fracture assessment (VFA) exams to measure abdominal aortic calcification, concluding that “…a high level of abdominal aortic calcification (AAC) detected on VFA images is predictive of incident myocardial infarction or stroke among elderly Caucasian women, independent of other clinical CVD (cardiovascular disease) risk factors.”

The study, titled "Abdominal Aortic Calcification Detected on Lateral Spine Images from a Bone Densitometer Predicts Incident Myocardial Infarction or Stroke in Older Women," indicates that physicians should use the opportunity of a VFA scan to look for evidence of cardiovascular disease.

“Previous work has shown that it is cost effective to do VFA scans in many postmenopausal women to detect vertebral fracture, and prescribe osteoporosis treatment medication when such a vertebral fracture is seen.” says lead author, John Schousboe, M.D. of Park Nicollet Health Services in Minneapolis, MN. “This is particularly important in women, since two-thirds of women who died suddenly of coronary heart disease have no prior symptoms.”

“This study found that AAC had a similar predictive strength for cardiovascular disease (CVD) as the Framingham Point score. The Framingham Point score combines the traditional risk factors of total cholesterol, HDL, blood pressure, hypertension treatment and smoking to predict 10-year cardiovascular heart disease risk” says co-author Eugene McCloskey, M.D., of Sheffield University, UK. “Additionally, we found that this predictive ability of AAC was independent of the all of the traditional CVD risk factors we collected in the study.”

For more information: www.hologic.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now